Effects of endothelium/leukocytes/platelet interaction on myocardial ischemia - reperfusion injury

Citation
H. Habazettl et al., Effects of endothelium/leukocytes/platelet interaction on myocardial ischemia - reperfusion injury, Z KARDIOL, 89, 2000, pp. 92-95
Citations number
12
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Journal title
ZEITSCHRIFT FUR KARDIOLOGIE
ISSN journal
0300-5860 → ACNP
Volume
89
Year of publication
2000
Supplement
9
Pages
92 - 95
Database
ISI
SICI code
0300-5860(2000)89:<92:EOEIOM>2.0.ZU;2-1
Abstract
Platelet fibrinogen receptor (GPIIb/IIIa) antagonists clinically improve th e effectiveness of thrombolysis or PTCA in treatment of acute myocardial in farction. 7E3Fab, the chimeric Fab fragment of a monoclonal GPIIb/IIIa anti body, reduces the incidence of death, reinfarction or restenosis in patient s and may improve blood flow and regional wall motion in reperfused myocard ium. Besides inhibition of platelet aggregation, 7E3Fab may block fibrinoge n bridging between the polymorphonuclear neutrophil (PMN) adhesion molecule MAC-1 and platelet GP IIb/IIIa, thus attenuating interaction of platelets with PMN. Experimentally, the interaction of platelets with PMN exacerbated postischemic myocardial stunning. In our own studies in isolated guinea pig hearts, human PMN, platelets and fibrinogen where simultaneously infused during the initial reperfusion peri od after 15 min of global ischemia. FAGS analysis of cells in the coronary effluant revealed that 7E3Fab reduced platelet GP IIb/IIIa expression to 10 % of baseline. PMN-platelet aggregate formation in the coronary effluate w as markedly reduced by 7E3Fab, parallel to a decrease of PMN-platelet aggre gates found by in situ double fluorescence microscopy in the postischemic c oronary vasculature. The inhibition of PMN-platelet aggregate formation by 7E3Fab treatment coincided with a significant improvement of external heart work, which suffered a 50 % reduction after ischemia, reperfusion, and exp osure to PMN, platelets and fibrinogen. Obviously application of 7E3Fab inhibits formation and coronary retention o f PMN-platelet aggregates in the postischemic, reperfused myocardium. This effect may contribute to the clinically observed beneficial effects of this adjuvant treatment after myocardial ischemia.